Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study

By Thigpen J.T.   Blessing J.A.   Olt G.   Lentz S.S.   Bell J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 581-586

Elsevier

Access to resources Recommend Favorite

Treatment of Relapsed Carcinoma of the Ovary with Single-Agent Paclitaxel Following Exposure to Paclitaxel and Platinum Employed as Initial Therapy

By Zanotti K.M.   Belinson J.L.   Kennedy A.W.   Webster K.D.   Markman M.  

Gynecologic Oncology, Vol. 79, Iss. 2, 2000-11 ,pp. : 211-215

Elsevier

Access to resources Recommend Favorite

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

By Markman M.   Webster K.   Zanotti K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 593-596

Elsevier

Access to resources Recommend Favorite

A case of chronic paclitaxel administration in ovarian cancer

By von Gruenigen V.E.   Karlen J.R.   Waggoner S.E.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 532-535

Elsevier

Access to resources Recommend Favorite

Phase I Trial of Ifosfamide and 24-h Infusional Paclitaxel in Pelvic Malignancies: A Gynecologic Oncology Group Study

By Markman M.   Spriggs D.   Burger R.A.   Carson L.F.   Lentz S.S.   Gallion H.  

Gynecologic Oncology, Vol. 80, Iss. 3, 2001-03 ,pp. : 359-363

Elsevier

Access to resources Recommend Favorite